Page last updated: 2024-08-24

irinotecan and FMR1-Related Primary Ovarian Insufficiency

irinotecan has been researched along with FMR1-Related Primary Ovarian Insufficiency in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Tanaka, T; Umesaki, N; Utsunomiya, T	1
Tanaka, T; Umesaki, N; Utsunomiya, H; Utsunomiya, T	2

Reviews

1 review(s) available for irinotecan and FMR1-Related Primary Ovarian Insufficiency

Article	Year
[Prevention of anticancer drug-induced premature ovarian failure]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 4 Topics: Animals; Antineoplastic Agents; Camptothecin; Female; Freezing; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Irinotecan; Leuprolide; Organ Preservation; Ovary; Primary Ovarian Insufficiency	2006

Other Studies

2 other study(ies) available for irinotecan and FMR1-Related Primary Ovarian Insufficiency

Article	Year
A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. International journal of oncology, 2008, Volume: 32, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Disease Models, Animal; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Female; Granulosa Cells; Immunohistochemistry; In Situ Nick-End Labeling; Injections, Intraperitoneal; Irinotecan; Mice; Organ Culture Techniques; Primary Ovarian Insufficiency; Recombinant Proteins; Topoisomerase I Inhibitors; Up-Regulation	2008
Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncology reports, 2008, Volume: 19, Issue:5 Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms	2008

Article

Year

A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.

International journal of oncology, 2008, Volume: 32, Issue:5

Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Disease Models, Animal; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Female; Granulosa Cells; Immunohistochemistry; In Situ Nick-End Labeling; Injections, Intraperitoneal; Irinotecan; Mice; Organ Culture Techniques; Primary Ovarian Insufficiency; Recombinant Proteins; Topoisomerase I Inhibitors; Up-Regulation

2008

Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women.

Oncology reports, 2008, Volume: 19, Issue:5

Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Middle Aged; Ovarian Neoplasms; Ovary; Perimenopause; Premenopause; Primary Ovarian Insufficiency; Treatment Outcome; Uterine Cervical Neoplasms

2008